Chimerix Inc.'s decision Friday to cancel trials of its antiviral brincidofovir to protect against Ebola in the face of declining numbers of new infections, and thus dwindling numbers of test subjects, brought into sharp relief the hard choices small companies need to make when choosing to develop experimental treatments for neglected tropical diseases.